On April 1, 2026, the FDA approved Eli Lilly's oral GLP-1 therapy Foundayo. It is the second oral GLP-1 therapy available, following the release of Wegovy tablets in January.

The effects of Foundayo were studied in a 72-week trial enrolling 3172 overweight adults. Foundayo doses of 6 mg, 12 mg, and 36 mg caused 7.5%, 8.4%, and 11.2% weight loss, respectively. This is slightly less than the Wegovy tablet, which causes 13.6% weight loss at its highest dose. Zepbound and Wegovy injections are also significantly more effective, with average weight losses of 21% and 16%, respectively. Foundayo side effects at the highest dose include the following: nausea (35%), diarrhea (25%), constipation (24%), vomiting (24%), and stomach upset (13%). One advantage Foundayo has over Wegovy tablets is that it can be taken without regard to food, whereas Wegovy tablets must be taken on an empty stomach, with no food or drink allowed for 30 minutes afterward. Pricing for Foundayo is as follows:

• 0.8 mg: $149 per month
• 2.5 mg: $199 per month
• 5.5 mg: $299 per month
• 9 mg: $299 per month
• 14.5 mg: $299 per month ^✝
• 17.2 mg: $299 per month ^✝

• ^✝For the 14.5 mg and 17.2 mg doses, LillyDirect requires that refills be purchased within 45 days of the delivery date of the previous prescription to maintain the $299 price. If the refill purchase is completed more than 45 days after delivery of the previous prescription, pricing will be $349.

Foundayo is another option in the rapidly evolving weight-loss drug class. Its primary advantages include the following:

• It is taken orally, appealing to people who do not like injections
• Can be taken without regard to food (Wegovy tablets must be taken on an empty stomach, with no food or drink allowed for 30 minutes afterward)
• Has similar pricing to the Wegovy tablet, which is currently the cheapest GLP-1 therapy

• LillyDirect Foundayo page